Based on the earnings transcript for Amgen Inc., here are the key points that influence the short-term impact on the stock price:

1. **Strong Revenue and Earnings Growth**: Amgen reported solid revenue and earnings growth, driven by the performance of key products like Enbrel, Prolia, and XGEVA. This positive performance is likely to be well-received by investors[1][3][5].

2. **Increased Guidance**: The company updated its full-year guidance for revenues and adjusted earnings per share, indicating continued momentum and confidence in their business strategy. This typically has a positive impact on investor sentiment[1][3][5].

3. **Pipeline Progress**: Amgen highlighted significant advancements in its pipeline, including promising data for romosozumab (AMG 785) and AMG 145, which could lead to future growth opportunities and reinforce investor confidence[1][3][5].

4. **Operational Efficiency and Cost Management**: The company emphasized its focus on expense discipline and operational efficiency, which contributed to strong free cash flows and is likely to be viewed positively by investors[1][3].

5. **Market and Competitive Dynamics**: While there are competitive pressures, particularly from biosimilars and new entrants in the market, Amgen's established products and strong relationships with customers are expected to mitigate these risks to some extent[1][3][5].

Given these points, the overall tone of the earnings call is positive, highlighting strong performance, robust pipeline advancements, and effective cost management. This is likely to result in a positive impact on the stock price in the short term.

**Rating: 1**